Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Abnormalities, Multiple | 3 | 2022 | 109 | 2.240 |
Why?
|
| Musculoskeletal Abnormalities | 2 | 2021 | 3 | 1.550 |
Why?
|
| Skin Neoplasms | 2 | 2020 | 375 | 0.990 |
Why?
|
| Cardiomyopathies | 2 | 2021 | 167 | 0.880 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2022 | 9 | 0.880 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2022 | 7 | 0.880 |
Why?
|
| Skin Ulcer | 1 | 2022 | 19 | 0.880 |
Why?
|
| Darier Disease | 1 | 2022 | 1 | 0.850 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 52 | 0.810 |
Why?
|
| Dermatitis | 1 | 2021 | 28 | 0.800 |
Why?
|
| Ectodermal Dysplasia | 1 | 2021 | 8 | 0.790 |
Why?
|
| Dwarfism | 1 | 2020 | 5 | 0.770 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2020 | 7 | 0.760 |
Why?
|
| Hemangioma | 1 | 2020 | 51 | 0.730 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2019 | 6 | 0.720 |
Why?
|
| Intellectual Disability | 1 | 2021 | 114 | 0.720 |
Why?
|
| Orofaciodigital Syndromes | 1 | 2017 | 4 | 0.640 |
Why?
|
| Keratosis | 1 | 2017 | 17 | 0.630 |
Why?
|
| Tretinoin | 1 | 2017 | 92 | 0.610 |
Why?
|
| Drainage | 1 | 2017 | 133 | 0.600 |
Why?
|
| Nevus, Pigmented | 1 | 2017 | 30 | 0.590 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 78 | 0.590 |
Why?
|
| Infant | 7 | 2021 | 2891 | 0.510 |
Why?
|
| Granuloma, Pyogenic | 1 | 2013 | 5 | 0.480 |
Why?
|
| Timolol | 1 | 2013 | 10 | 0.480 |
Why?
|
| Child | 8 | 2022 | 6400 | 0.480 |
Why?
|
| Propranolol | 1 | 2013 | 102 | 0.460 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 189 | 0.440 |
Why?
|
| Syndrome | 3 | 2021 | 255 | 0.420 |
Why?
|
| Humans | 17 | 2022 | 68525 | 0.340 |
Why?
|
| Desmoplakins | 2 | 2021 | 14 | 0.260 |
Why?
|
| Eyebrows | 1 | 2022 | 2 | 0.210 |
Why?
|
| Collagen Type VI | 1 | 2022 | 5 | 0.210 |
Why?
|
| Female | 8 | 2022 | 38015 | 0.210 |
Why?
|
| Skin | 2 | 2021 | 451 | 0.200 |
Why?
|
| Hair | 1 | 2021 | 46 | 0.200 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2021 | 7 | 0.200 |
Why?
|
| Ultraviolet Therapy | 1 | 2021 | 9 | 0.200 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 186 | 0.200 |
Why?
|
| Phototherapy | 1 | 2021 | 28 | 0.190 |
Why?
|
| Phimosis | 1 | 2020 | 2 | 0.190 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 37 | 0.190 |
Why?
|
| Skin Abnormalities | 1 | 2020 | 11 | 0.190 |
Why?
|
| Homozygote | 1 | 2020 | 119 | 0.190 |
Why?
|
| Rhombencephalon | 1 | 2019 | 7 | 0.180 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2019 | 12 | 0.180 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2019 | 43 | 0.180 |
Why?
|
| Arthritis, Psoriatic | 1 | 2019 | 3 | 0.170 |
Why?
|
| Skin Diseases | 1 | 2021 | 122 | 0.170 |
Why?
|
| Nail Diseases | 1 | 2019 | 13 | 0.170 |
Why?
|
| Joint Instability | 1 | 2020 | 87 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 163 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 245 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 151 | 0.160 |
Why?
|
| Face | 1 | 2017 | 46 | 0.160 |
Why?
|
| Mosaicism | 1 | 2017 | 21 | 0.150 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2015 | 2 | 0.140 |
Why?
|
| Leukemoid Reaction | 1 | 2015 | 2 | 0.140 |
Why?
|
| GATA1 Transcription Factor | 1 | 2015 | 19 | 0.140 |
Why?
|
| Tinea Capitis | 1 | 2015 | 2 | 0.130 |
Why?
|
| Trichophyton | 1 | 2015 | 2 | 0.130 |
Why?
|
| Child, Preschool | 3 | 2021 | 3185 | 0.130 |
Why?
|
| Mutation | 2 | 2017 | 1213 | 0.130 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2021 | 756 | 0.120 |
Why?
|
| Down Syndrome | 1 | 2015 | 119 | 0.120 |
Why?
|
| Quality of Life | 1 | 2022 | 1515 | 0.120 |
Why?
|
| Administration, Topical | 1 | 2013 | 111 | 0.120 |
Why?
|
| Adolescent | 2 | 2022 | 8903 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 785 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2019 | 2688 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 1139 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2015 | 7028 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2021 | 2453 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3256 | 0.050 |
Why?
|
| Male | 4 | 2021 | 37281 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2021 | 242 | 0.050 |
Why?
|
| Antibodies, Antinuclear | 1 | 2021 | 171 | 0.050 |
Why?
|
| Neurogenesis | 1 | 2019 | 32 | 0.050 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 61 | 0.050 |
Why?
|
| Nerve Fibers | 1 | 2019 | 77 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2020 | 159 | 0.040 |
Why?
|
| Mothers | 1 | 2021 | 172 | 0.040 |
Why?
|
| Acute Disease | 1 | 2021 | 658 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 328 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 2093 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2015 | 41 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 1692 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 191 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1174 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 467 | 0.030 |
Why?
|
| Young Adult | 1 | 2021 | 5708 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 2004 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 7264 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 8472 | 0.020 |
Why?
|
| Adult | 1 | 2021 | 21375 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 20877 | 0.010 |
Why?
|